News Releases

November 1, 2016

RepliCel Life Sciences Announces Closing of Private Placement
Completed Financing Positions RepliCel Through Upcoming Milestones  VANCOUVER, BC – October 31, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”) (OTCQB: REPCD)... Read full article

October 7, 2016

RepliCel Life Sciences Amends Terms of Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES VANCOUVER, BC – October 7, 2016 – RepliCel... Read full article

September 27, 2016

RepliCel Announces Debt Settlement
VANCOUVER, BC – September 27, 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCD) (TSXV: RP) (Frankfurt: P6P2), (“RepliCel” or the “Company”), a clinical-stage regenerative... Read full article

September 26, 2016

RepliCel Provides Update on Shiseido License and Co-Development for RCH-01
VANCOUVER, BC – September 26 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCD) (TSXV: RP) (Frankfurt: P6P2), (“RepliCel” or the “Company”), a clinical-stage regenerative... Read full article

September 14, 2016

RepliCel Life Sciences Announces Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES Funding proceeds anticipated to see RepliCel through several... Read full article

August 9, 2016

Replicel Life Sciences Share Consolidation Approved
Capital Structure Restructuring Expected to Lead to Financing and Milestones  VANCOUVER, BC – August 9, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the... Read full article

July 22, 2016

Replicel Life Sciences Continues Restructuring with Share Structure Consolidation
VANCOUVER, BC – July 22, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”) (OTCQB: REPCF) (TSXV: RP) (Frankfurt: P6P1), a clinical stage... Read full article

July 21, 2016

RepliCel’s Cell Therapy for Pattern Baldness Proceeds to Clinical Trial Launch in Japan
VANCOUVER, BC – July 21, 2016 – RepliCel Life Sciences Inc. (OTCQB: REPCF) (TSXV: RP) (Frankfurt: P6P1), (“RepliCel” or the “Company”), a clinical-stage regenerative... Read full article

April 29, 2016

Replicel Life Sciences Extends Warrant Expiry Dates and Amends Warrant Exercise Price
VANCOUVER, BC – April 29, 2016 – RepliCel Life Sciences Inc. (“RepliCel” or the “Company”) (OTCQB: REPCF) (TSXV: RP), a clinical stage regenerative medicine... Read full article

April 25, 2016

RepliCel Life Sciences conducts formal consultation review with Japan’s PMDA and receives unprecedented review fee reduction
Japan’s Pharmaceuticals and Medical Devices Agency reviews RepliCel’s pre-clinical, quality, and manufacturing data for its non-bulbar dermal sheath (NBDS) platform VANCOUVER, BC – April... Read full article